NCT05977803 Contribution of the CEST Sequence in the Characterization of Radionecrosis of Brain Metastases of Pulmonary Origin
| NCT ID | NCT05977803 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Condition | Brain Metastases |
| Study Type | INTERVENTIONAL |
| Enrollment | 60 participants |
| Start Date | 2024-02-15 |
| Primary Completion | 2029-02-15 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 60 participants in total. It began in 2024-02-15 with a primary completion date of 2029-02-15.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to determine whether the use of the CEST sequence would have diagnostic performance equivalent to the reference method of T2\* infusion with contrast injection in the diagnosis of radionecrosis of lung cancer brain metastases.
Eligibility Criteria
Inclusion Criteria: * Patients \> 18 years of age * Histologically proven primary lung cancer * Histologically proven or not brain metastases * Irradiated metastases * Inclusion in a treatment protocol for brain metastases by brain metastasis in toto or stereotactic or gamma-knife radiotherapy * Morphological increase of one or more lesions of secondary brain metastases on a follow-up MRI * Patients affiliated to a social security scheme Exclusion Criteria: * Opposition to the study * Contraindication to MRI * Refusal of imaging by the patient * Patient with state medical aid (unless exemption from affiliation) * Severe cognitive impairment making informed consent impossible * Patients under guardianship or deprived of liberty
Contact & Investigator
Augustin Gaudemer, MD
PRINCIPAL INVESTIGATOR
Assistance Publique - Hôpitaux de Paris
Frequently Asked Questions
Who can join the NCT05977803 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Brain Metastases. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05977803 currently recruiting?
Yes, NCT05977803 is actively recruiting participants. Contact the research team at augustin.gaudemer@aphp.fr for enrollment information.
Where is the NCT05977803 trial being conducted?
This trial is being conducted at Paris, France.
Who is sponsoring the NCT05977803 clinical trial?
NCT05977803 is sponsored by Assistance Publique - Hôpitaux de Paris. The principal investigator is Augustin Gaudemer, MD at Assistance Publique - Hôpitaux de Paris. The trial plans to enroll 60 participants.